The Conversation (0)
ProMIS Neurosciences Issues Narrated Overview of Second Quarter 2018 Results
Aug. 29, 2018 09:39AM PST
Biotech Investing
ProMIS Neurosciences (TSX:PMN) has announced it has issued a narrated overview of its second quarter 2018 foperational results. “We continued to make significant progress on three main priorities in the second quarter of 2018”, stated ProMIS Executive Chairman, Eugene Williams. “First, to maintain PMN310 on track for clinical trial start in the second half of 2019 …
ProMIS Neurosciences (TSX:PMN) has announced it has issued a narrated overview of its second quarter 2018 foperational results.
“We continued to make significant progress on three main priorities in the second quarter of 2018”, stated ProMIS Executive Chairman, Eugene Williams. “First, to maintain PMN310 on track for clinical trial start in the second half of 2019 with initiation of cell line development supporting product manufacturing; second, to differentiate the oligomer selectivity of PMN310 as best in class profile for the treatment of Alzheimer’s disease (AD) versus other, less selective amyloid-beta (Ab) directed therapies in development; and third, to expand our portfolio by developing therapeutic antibodies targeting toxic oligomers of alpha-synuclein for Parkinson’s disease (PD) and toxic aggregates of Tar-DNA binding protein (TDP43) for ALS, with a view to partnering these assets.”
The narrated overview can be found on the ProMIS Neurosciences website by clicking on the link below:
https://bit.ly/2wsr8Op